Get the Stockscreener App
56.19
0.80%
-0.3994
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $56.19, with a volume of 5.95M.
It is down -0.80% in the last 24 hours and down -2.66% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.59
Open:
$56.44
24h Volume:
5.95M
Relative Volume:
0.48
Market Cap:
$114.65B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
15.77
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-7.35%
1M Performance:
-2.66%
6M Performance:
+20.23%
1Y Performance:
+17.88%
1-Day Range:
$55.57
$56.90
1-Week Range:
$55.57
$60.09
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.15 | 115.56B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
971.56 | 880.19B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
222.02 | 540.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
202.47 | 362.65B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
182.45 | 286.78B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
145.29 | 283.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Premier Fund Managers Ltd Invests $11.63 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Principal Financial Group Inc. Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions - Yahoo Finance
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb shows why pharmaceutical factories are ahead of the rest of American manufacturing on AI - Startup Fortune
QRG Capital Management Inc. Purchases 21,399 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bokf Na Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily
Cytokinetics stock adds more than $1 billion of valuation in a single day — Here's why - The Business Journals
Bristol-Myers posts Q1 beat thanks to growth portfolio - MSN
Bristol Myers Squibb Company (BMY) is attracting investor attention: Here is what you should know - MSN
Bristol Myers Squibb Company $BMY Shares Sold by RNC Capital Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Shares Bought by Intact Investment Management Inc. - MarketBeat
In FIFA-Tied Corporate Campaign, Bristol Myers Squibb 'Won't Lose' 05/05/2026 - MediaPost
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
BMO Capital reiterates Bristol-Myers Squibb stock rating at Market Perform By Investing.com - Investing.com India
BMO Capital reiterates Bristol-Myers Squibb stock rating at Market Perform - Investing.com
Varma Mutual Pension Insurance Co Boosts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™ - Messenger-Inquirer
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
A Look At Bristol Myers Squibb (BMY) Valuation After Its Q1 2026 Earnings Beat And Reaffirmed Guidance - simplywall.st
Bristol-Myers Squibb Company Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Horizon Investments LLC Sells 137,701 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Robertson Stephens Wealth Management LLC Increases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Caisse Des Depots ET Consignations Trims Position in Bristol Myers Squibb Company $BMY - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Margin Strength In Q1 2026 Challenges Bearish Earnings Narratives - simplywall.st
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.18% on May 1: Drivers Behind the Movement - TradingKey
Bristol-Myers Loses Venue Fight to Texas in Plavix Litigation - Bloomberg Law News
Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript - Insider Monkey
Oppenheimer Asset Management Inc. Sells 46,381 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - Yahoo Finance
Brookstone Value Stock ETF's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Q1 2026 Earnings Call Highlights: - GuruFocus
Is Bristol Myers Squibb (BMY) Still Attractively Priced After Its Strong 1 Year Share Price Gain - simplywall.st
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMO raises Bristol-Myers Squibb stock price target on Eliquis beat - Investing.com India
SIIT U.S. Managed Volatility Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
LSV VALUE EQUITY FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - MarketBeat
Is Bristol-Myers Squibb Co (BMY) Overvalued After 5.2% Rally? GF - GuruFocus
Bristol-Myers Squibb (BMY) Reports Solid Q1 2026 Results with Po - GuruFocus
MSN Money - MSN
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday? - Benzinga
Bristol Myers (BMY) Q1 2026 Earnings Transcript - The Motley Fool
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):